{"id":60795,"date":"2024-02-28T07:08:53","date_gmt":"2024-02-28T07:08:53","guid":{"rendered":"https:\/\/medsname.com\/atrest\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"atrest","status":"publish","type":"product","link":"https:\/\/medsbase.com\/hu\/product\/atrest\/","title":{"rendered":"Atrest"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Atrest?<\/h3>\n

Atrest<\/strong> or\u00e1lis tetrabenazine<\/strong> (12.5 mg) tablet \u2014 a VMAT2 (vesicular monoamine transporter 2) inhibitor<\/strong> specifically approved for the treatment of chorea associated with Huntington disease<\/strong>. It works by depleting dopamine from nerve terminals, reducing the involuntary writhing and jerking movements that characterise Huntington chorea. Starting dose: 12,5 mg naponta egyszer<\/strong>, increased weekly by 12.5 mg to a maximum of 37.5 mg\/dose (75–100 mg\/day)<\/strong>, always divided into 2–3 doses. Patients receiving >50 mg\/day require CYP2D6 genotyping<\/strong>. Common side effects: sedation, akathisia, depression, parkinsonism, insomnia. Black-box warning:<\/strong> increases risk of depression and suicidality in Huntington patients \u2014 monitor mood closely.<\/p>\n<\/div>\n

\nMit kapsz a MedsBase-n\u00e1l:<\/strong> WHO-GMP min\u0151s\u00edt\u00e9s\u0171 gy\u00e1rt\u00f3 \u00b7 Diszkr\u00e9t csomagol\u00e1s \u00b7 Vil\u00e1gszerte sz\u00e1ll\u00edt\u00e1s \u00b7 1.400+ hiteles\u00edtett v\u00e1s\u00e1rl\u00f3i v\u00e9lem\u00e9ny<\/a>\n<\/div>\n

\ud83d\udce6 Minden rendel\u00e9st fedez a \u00dajrak\u00fcld\u00e9si Garancia<\/strong><\/a> \u2014 ha a csomagod nem \u00e9rkezik meg 20 munkanapon bel\u00fcl, \u00fajrak\u00fcldj\u00fck.<\/p>\n

Mi\u00e9rt rendelj a MedsBase-r\u00f3l<\/h3>\n

Generikus gy\u00f3gyszereink WHO-GMP min\u0151s\u00edt\u00e9s\u0171 gy\u00e1rt\u00f3kt\u00f3l sz\u00e1rmaznak, \u00e9s diszkr\u00e9t, egyszer\u0171 csomagol\u00e1sban sz\u00e1ll\u00edtjuk \u0151ket vil\u00e1gszerte \u2014 a csomagon nem szerepel a gy\u00f3gyszer neve. A k\u00e1rty\u00e1s fizet\u00e9sek egy szab\u00e1lyozott feldolgoz\u00f3n kereszt\u00fcl t\u00f6rt\u00e9nnek (a sz\u00e1mlale\u00edr\u00e1sok egy szab\u00e1lyozott k\u00e1rtyafizet\u00e9si feldolgoz\u00f3t tartalmaznak \u2014 soha nem \u201cMedsBase\u201d vagy b\u00e1rmilyen gy\u00f3gyszer neve). Kriptovalut\u00e1t \u00e9s SEPA banki \u00e1tutal\u00e1st is elfogadunk. Minden rendel\u00e9st a Reshipment Assurance Policy biztos\u00edt\u00e9k fedez.<\/p>\n

What Is Atrest?<\/h2>\n

Atrest is an oral tablet containing tetrabenazine 12.5 mg<\/strong>. Tetrabenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor<\/strong> — the first drug specifically approved for the treatment of chorea associated with Huntington disease<\/strong>.<\/p>\n

By depleting presynaptic dopamine stores, tetrabenazine reduces the involuntary, dance-like movements (chorea) that characterise Huntington disease without the tardive dyskinesia risk of traditional dopamine receptor blockers. It was first used in Europe in the 1970s and gained FDA approval in 2008 as Xenazine<\/strong>. Atrest is manufactured by a WHO-GMP certified facility and is bioequivalent to the originator brand at the same strength.<\/p>\n

How Does Atrest (Tetrabenazine) Work?<\/h2>\n

Tetrabenazine irreversibly inhibits VMAT2<\/strong>, the protein responsible for packaging dopamine, serotonin, and norepinephrine into synaptic vesicles. By blocking VMAT2, the drug depletes presynaptic monoamine stores \u2014 predominantly dopamine in the basal ganglia. Excessive dopaminergic activity in the striatum is the primary driver of choreiform movements in Huntington disease, so reducing dopamine availability at the post-synaptic receptor directly suppresses chorea.<\/p>\n

The drug is extensively metabolised by CYP2D6 into two active metabolites (α-HTBZ and β-HTBZ) that account for most of the clinical effect. CYP2D6 poor metabolisers<\/strong> have significantly higher plasma levels, which is why genotyping is required before exceeding 50 mg\/day.<\/p>\n

D\u00f3zis \u00e9s alkalmaz\u00e1s<\/h2>\n\n\n\n\n\n\n\n\n
H\u00e9t<\/th>\nDaily Dose<\/th>\nSzed\u00e9si rend<\/th>\n<\/tr>\n<\/thead>\n
1. h\u00e9t<\/td>\n12.5 mg<\/td>\nOnce daily (morning)<\/td>\n<\/tr>\n
2. h\u00e9t<\/td>\n25 mg<\/td>\n12.5 mg twice daily<\/td>\n<\/tr>\n
Week 3+<\/td>\n37.5–50 mg<\/td>\nDivided into 2–3 doses<\/td>\n<\/tr>\n
Maxim\u00e1lis<\/td>\n75–100 mg\/day*<\/td>\n*CYP2D6 genotyping required >50 mg\/day<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Bevehet\u0151 \u00e9tkez\u00e9ssel vagy an\u00e9lk\u00fcl. No single dose should exceed 37.5 mg.<\/strong> If treatment is interrupted for >5 days, re-titrate from 12.5 mg.<\/p>\n

Mell\u00e9khat\u00e1sok<\/h2>\n
⚠ Black-box warning \u2014 Depression & suicidality:<\/strong> Tetrabenazine increases the risk of depression and suicidal thoughts\/behaviour in patients with Huntington disease. Do not use in patients who are actively suicidal or have untreated\/inadequately treated depression. Patients and caregivers should be alerted to monitor for emerging or worsening depression, suicidality, or unusual changes in behaviour.<\/div>\n

Common (\u226510%):<\/strong> sedation\/somnolence, fatigue, insomnia, depression, akathisia (restlessness), anxiety, nausea.<\/p>\n

S\u00falyos:<\/strong> parkinsonism (dose-related), neuroleptic malignant syndrome (rare), QTc prolongation (avoid in congenital long-QT syndrome), dysphagia (increased aspiration risk in Huntington patients).<\/p>\n

Figyelmeztet\u00e9sek \u00e9s el\u0151vigy\u00e1zatoss\u00e1g<\/h2>\n